Vismodegib
- Generic Name
- Vismodegib
- Brand Names
- Erivedge
- Drug Type
- Small Molecule
- Chemical Formula
- C19H14Cl2N2O3S
- CAS Number
- 879085-55-9
- Unique Ingredient Identifier
- 25X868M3DS
- Background
Vismodegib is an orally active small molecule that inhibits the hedgehog signaling pathway by binding to and inhibiting the transmembrane protein smoothened homologue (SMO). It was discovered by high-throughput screening of a library of small-molecule compounds and subsequent optimization through medicinal chemistry. Since it targets the hedgehog signaling p...
- Indication
用于不能手术或放疗的局部晚期皮肤基底细胞癌患者和肿瘤已转移的患者。
- Associated Conditions
- Locally Advanced Basal Cell Carcinoma, Metastatic Basal cell carcinoma
- Associated Therapies
- -
Erivedge (Vismodegib) in the Treatment of Pediatric Patients With Refractory Pontine Glioma
- First Posted Date
- 2013-01-23
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- Giselle Sholler
- Target Recruit Count
- 9
- Registration Number
- NCT01774253
- Locations
- 🇺🇸
Phoenix Children's Hospital, Phoenix, Arizona, United States
🇺🇸Helen DeVos Children's Hospital, Grand Rapids, Michigan, United States
A Drug-Drug Interaction Study of the Effect of Rabeprazole, Itraconazole or Fluconazole on the Pharmacokinetics of Vismodegib
- Conditions
- Interventions
- First Posted Date
- 2013-01-21
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 92
- Registration Number
- NCT01772290
Effect on Tumor Perfusion of a Chemotherapy Combining Gemcitabine and Vismodegib Before Surgery in Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2012-10-24
- Last Posted Date
- 2012-10-24
- Lead Sponsor
- Jean-Luc Van Laethem
- Target Recruit Count
- 21
- Registration Number
- NCT01713218
- Locations
- 🇧🇪
Erasme University Hospital (ULB), Brussels, Belgium
🇧🇪Antwerp University Hospital (UZA), Edegem, Antwerpen, Belgium
Vismodegib in Treating Patients With Basal Cell Carcinoma (BCC)
- Conditions
- Interventions
- First Posted Date
- 2012-06-29
- Last Posted Date
- 2017-12-08
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 15
- Registration Number
- NCT01631331
- Locations
- 🇺🇸
Stanford University, Stanford, California, United States
Study of Vismodegib in Combination With Temozolomide Versus Temozolomide Alone in Patients With Medulloblastomas With an Activation of the Sonic Hedgehog Pathway
- Conditions
- Interventions
- First Posted Date
- 2012-05-17
- Last Posted Date
- 2019-05-21
- Lead Sponsor
- Centre Leon Berard
- Target Recruit Count
- 24
- Registration Number
- NCT01601184
- Locations
- 🇫🇷
Institut de Cancérologie de l'Ouest - René Gauducheau, St Herblain, Loire Atlantique, France
🇫🇷Institut Bergonié, Bordeaux, France
🇫🇷Institut Claudius Régaud (iuct-oncopole), Toulouse, Haute-Garonne, France
Trial Comparing the Effects of Intermittent Vismodegib vs. PDT in Patients With Multiple Basal Cell Carcinomas
- Conditions
- Interventions
- First Posted Date
- 2012-03-16
- Last Posted Date
- 2020-11-02
- Lead Sponsor
- UCSF Benioff Children's Hospital Oakland
- Target Recruit Count
- 24
- Registration Number
- NCT01556009
- Locations
- 🇺🇸
Children's Hospital Oakland Research Institiute, Oakland, California, United States
🇺🇸Children's Hospital Research Center Oakland, Oakland, California, United States
🇺🇸Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, New York, New York, United States
A Study of Vismodegib in Patients With Advanced Solid Malignancies Including Hepatocellular Carcinoma With Varying Degrees of Renal or Hepatic Function
- First Posted Date
- 2012-03-07
- Last Posted Date
- 2016-05-23
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 31
- Registration Number
- NCT01546519
Vismodegib for Treatment of Basal Cell Carcinoma
- First Posted Date
- 2012-03-05
- Last Posted Date
- 2014-09-26
- Lead Sponsor
- Abel Torres, MD
- Target Recruit Count
- 3
- Registration Number
- NCT01543581
Sirolimus and Vismodegib in Treating Patients With Solid Tumors or Pancreatic Cancer That is Metastatic or Cannot Be Removed By Surgery
- Conditions
- Interventions
- First Posted Date
- 2012-02-23
- Last Posted Date
- 2019-04-08
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 31
- Registration Number
- NCT01537107
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸Mayo Clinic Campus in Florida, Jacksonville, Florida, United States
🇺🇸Mayo Clinic Campus in Arizona, Scottsdale, Arizona, United States
STEVIE: A Study of Vismodegib in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma
- First Posted Date
- 2011-06-07
- Last Posted Date
- 2019-06-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1232
- Registration Number
- NCT01367665
- Locations
- 🇦🇺
Premier Specialists, Kogarah, New South Wales, Australia
🇦🇷Inst. de Oncologia Angel H. Roffo ; Servicio de Oncologia, Buenos Aires, Argentina
🇦🇺Skin and Cancer Foundation Australia, Westmead, New South Wales, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.